Evidence map›Paper›PMID 30264456›Full record

ArticleESC heart failure2018

Rationale and design for ENHANCE CRT: QLV implant strategy for non-left bundle branch block patients.

Jagmeet P Singh, Ronald D Berger, Rahul N Doshi, Michael Lloyd, Douglas Moore, Emile G Daoud, ENHANCE CRT Study Group

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01983293 (Cardiac Resynchronization Therapy), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01983293 nacompletednot on this map

Cardiac Resynchronization Therapy (CRT) Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients (ENHANCE CRT). A Prospective, Randomized, Postmarket, Pilot Study.

TypeinterventionalSponsorAbbott Medical DevicesRan2013 to 2018Enrolled248ConditionsNon-left Bundle Branch Block, Ischemic or Non-ischemic CardiomyopathyArmsQLV based implant strategy, Standard of care implant strategy
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. CRT Optimization: What Is New? What Is Necessary?Current treatment options in cardiovascular medicine · 2019
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jagmeet P SinghMassachusetts General Hospital, Boston, MA, USA.
Ronald D BergerJohns Hopkins, Baltimore, MD, USA.
Rahul N DoshiUniversity of Southern California, Los Angeles, CA, USA.
Michael LloydEmory University Hospital, Atlanta, GA, USA.
Douglas MooreSt John Hospital and Medical Center, Detroit, MI, USA.
Emile G DaoudThe Ohio State University, Columbus, OH, USA.
ENHANCE CRT Study GroupThe Ohio State University, Columbus, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsHistorically, cardiac resynchronization therapy (CRT) response in non-left bundle branch block (non-LBBB) patients has been suboptimal in comparison with that observed in left bundle branch block patients. The electrical activation pattern of the left ventricle (LV) is different between these two QRS morphologies. Small non-randomized studies have suggested that targeting the LV wall with greatest electrical delay may be superior to conventional anatomical pacing from the lateral wall in non-LBBB patients. This article outlines the design and rationale of a prospective, randomized, pilot study, which assesses the effect of a non-traditional LV lead implant strategy on the clinical composite score after 12 months of follow-up in a non-LBBB patient population.

methodsAll patients will receive an Abbott quadripolar CRT-D system (Quartet 1458Q LV lead with Unify Quadra™, Quadra Assura™ CRT-D or any market-approved CRT-D device with quadripolar pacing capabilities). Patients will be randomized in a 2:1 ratio between a QLV-based implant strategy vs. standard of care. Up to 250 patients will be enrolled in the study.

conclusionsIf the primary endpoint is achieved, this study will provide important information about reducing the non-responder rate in non-LBBB patients and provide further evidence for the QLV-based implant strategy.

Indexed as

Cardiac Resynchronization Therapy DevicesBundle-Branch BlockDouble-Blind MethodElectrocardiographyEquipment DesignFollow-Up StudiesHeart VentriclesHumansMulticenter Studies as TopicPilot ProjectsProspective StudiesRandomized Controlled Trials as TopicTime FactorsVentricular Function, LeftCardiac resynchronization therapyImplant strategyNon-LBBBQLVQuartetRBBB

Identifiers

PMID30264456
PMCPMC6300807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.